Clinical trials: Drug Refractory Epilepsy
Drug Resistant Epilepsy, Seizure
NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
To evaluate the safety and efficacy of using NaviFUS™ system in patients with drug resistant epilepsy
- Conditions
- Drug Resistant Epilepsy, Seizure, Seizure Disorder, Epilepsy
- Trial name
- NCT04999046
- Testing
- NaviFUS System
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- NaviFUS Corporation
Drug-resistant Epilepsy, Focal-Onset Seizures
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset…
- Trial name
- ARISE (NCT03373383)
- Testing
- Padsevonil
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 411 people
- Sponsor
- UCB Biopharma S.P.R.L.
Focal Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- Trial name
- RISE 2 (NCT06132893)
- Testing
- BHV-7000
- Where
- 104 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- Biohaven Therapeutics Ltd.
Neuroblastoma
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
- Trial name
- NCT04106219
- Testing
- LY3295668 Erbumine, Topotecan, Cyclophosphamide
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 71 people
- Sponsor
- Eli Lilly and Company
Drug Resistant Epilepsy, Focal Seizure
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007
This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007.
- Trial name
- NCT06899230
- Testing
- iQ-007
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- iQure Australia Pty Ltd
Drug Resistant Epilepsy, Ketogenic Dieting
Management of Drug-resistant Epilepsy in Infants and Children: a Real-life Study of the Use of the Ketogenic Diet in France and the KetoCal® Range in Its Maintenance
This is a multicenter, prospective, observational, longitudinal study designed to describe the therapeutic value of the KetoCal® range in the maintenance of a ketogenic diet during the management of infants (from 5 months) and…
- Trial name
- KEOPS (NCT06075485)
- Testing
- Ketocal
- Where
- France
- Volunteers
- 133 people
- Sponsor
- Nutricia Nutrition Clinique
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Drug-Refractory Epilepsy
Rechargeable Implantable Vagus Nerve Stimulation System for Drug-Refractory Epilepsy
To evaluate the performance of automatic stimulation mode of a new rechargeable implantable vagus nerve stimulation system for drug-refractory epilepsy
- Trial name
- NCT05993117
- Testing
- G114R VNS system
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Intellectual Disability, Developmental Delay
Biomarker for Creatine Deficiency Syndromes (BioCDS)
Development of a new mass spectrometry-based biomarker for the ear-ly and sensitive diagnosis of the Creatine Deficiency Syndromes from dry-blood-spot sample
- Conditions
- Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder
- Trial name
- BioCDS (NCT02934854)
- Where
- 4 sites in Egypt, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Refractory Epilepsy
Product Surveillance Registry- Deep Brain Stimulation for Epilepsy
The purpose of this observational registry is to evaluate the long-term effectiveness, safety and performance of market-released Medtronic Neuromodulation products for Deep Brain Stimulation (DBS) for the treatment of refractory…
- Trial name
- MORE (NCT01521754)
- Where
- 27 sites in Austria, Belgium and 11 more
- Volunteers
- 191 people
- Sponsor
- MedtronicNeuro
Epilepsy
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
- Trial name
- NCT00368069
- Testing
- Keppra® extended release formulation - XR
- Where
- 34 sites in Brazil, Finland and 5 more
- Volunteers
- 158 people
- Sponsor
- UCB Pharma
Refractory Epilepsy, Focal Seizure
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers…
- Conditions
- Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures
- Trial name
- NCT04770337
- Testing
- STARSTIM device
- Where
- 32 sites in United States, Belgium and 2 more
- Volunteers
- 127 people
- Sponsor
- Neuroelectrics Corporation
Refractory Epilepsy in Children
Does VNS Interact With the Serotonergic and Immune System in Children With Intractable Epilepsy?
Clinical randomized controlled observer blinded add-on design. Additionally there will be a non-controlled follow-up phase of the study.
- Trial name
- NCT01378611
- Testing
- Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA
- Where
- 2 sites in Netherlands
- Volunteers
- 45 people
- Sponsor
- Epilepsiecentrum Kempenhaeghe
Seizures
Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy
This Phase 3 study is being conducted to evaluate the efficacy and safety of retigabine dosed at 900 mg/day and 600 mg/day, in three equally divided doses, compared with placebo in patients with epilepsy who are receiving up to…
- Trial name
- RESTORE2 (NCT00235755)
- Testing
- Retigabine
- Where
- 70 sites in United States, Australia and 11 more
- Volunteers
- 539 people
- Sponsor
- GlaxoSmithKline
Drug-Resistant Epilepsy, Focal-Onset Seizures
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for…
- Trial name
- DUET (NCT03739840)
- Testing
- Padsevonil
- Where
- 141 sites in United States, Australia and 26 more
- Volunteers
- 232 people
- Sponsor
- UCB Biopharma SRL
Seizures, Epilepsies, Partial
Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.
To evaluate the efficacy and safety of diazepam in the management of refractory epilepsy in selected patients who require intermittent medical intervention for the control of episodes of acute repetitive seizures.
- Conditions
- Seizures, Epilepsies, Partial, Epilepsy, Complex Partial, Epilepsy, Generalized
- Trial name
- NCT00319501
- Testing
- Vanquix Auto-Injector (Diazepam Injection)
- Where
- 86 sites in United States
- Volunteers
- 234 people
- Sponsor
- Pfizer
Epilepsy, Epilepsies, Partial
An Open-Label Extension Study to Evaluate the Safety and Effectiveness of RWJ 333369 in Patients With Epilepsy
The purpose of this study is to evaluate the safety and preliminary effectiveness of the novel compound RWJ-333369 in patients with partial onset seizures who are currently being treated with 1 or 2 concomitant antiepileptic…
- Trial name
- NCT00210652
- Testing
- RWJ 333369:
- Volunteers
- 47 people
- Sponsor
- SK Life Science, Inc.
Refractory Epilepsy, Development Delay
European Non-interventional Study on Refractory Epilepsy With Developmental Delay
This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review).
- Trial name
- NCT04398667
- Where
- 19 sites in France, Germany and 2 more
- Volunteers
- 93 people
- Sponsor
- Zogenix, Inc.
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Epilepsies, Partial, Epilepsy, Tonic-Clonic
Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study
Evaluate the initial safety and effectiveness of Microburst VNS stimulation in subjects with refractory epilepsy.
- Trial name
- Microburst (NCT03446664)
- Testing
- Microburst Stimulation
- Where
- 9 sites in United States, Belgium
- Volunteers
- 33 people
- Sponsor
- LivaNova